The CD109 Knockout NCI-H1299 Polyclonal Cells represent a CRISPR/Cas9-engineered polyclonal knockout cell population derived from the human NCI-H1299 non-small cell lung cancer (NSCLC) cell line. This polyclonal pool results from targeted disruption of the CD109 gene, yielding a genetically heterogeneous loss-of-function model that enables comprehensive analysis of CD109’s roles in signal transduction and cellular behavior.
The parental NCI-H1299 cell line originates from a lymph node metastasis of a lung adenocarcinoma patient, exhibiting an adherent epithelial morphology. It is a widely utilized model in NSCLC research for studying tumor cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT). Its metastatic derivation and retained signaling pathway responsiveness make it particularly relevant for exploring mechanisms of cancer progression.
CD109 encodes a glycosylphosphatidylinositol (GPI)-anchored cell surface co-receptor that negatively regulates transforming growth factor-?? (TGF-??) signaling. Mechanistically, CD109 interacts with TGF-?? receptor I and thrombospondin-1, promoting receptor internalization and degradation, thereby attenuating phosphorylation of the downstream effectors SMAD2 and SMAD3. Additionally, CD109 modulates integrin ??2??1-mediated adhesion and influences the JAK/STAT and PI3K/AKT pathways; it is regulated upstream by TGF-?? ligands, SMAD proteins, and STAT3, and it impacts targets including AKT, STAT1, and integrin-dependent signaling. By constraining SMAD2/3 transcriptional activity, CD109 restricts expression of EMT transcription factors such as Snail and ZEB1, highlighting its role in balancing TGF-??-driven cellular responses.
In NCI-H1299 cells, disruption of CD109 is predicted to enhance TGF-?? receptor stability and downstream signaling outputs, tipping the balance toward pro-migratory and invasive phenotypes. The polyclonal knockout cell population mirrors the heterogeneity of CD109 loss that may occur in tumor subpopulations, avoiding clonal bias and providing a more accurate representation of gene function in a cancer cell context. Consequently, this model enables robust investigation of how CD109-deficient cells respond to TGF-?? stimuli, whether through canonical SMAD2/3 nuclear translocation, non-canonical AKT activation, or integrin-mediated adhesion changes, all of which are central to EMT and metastatic dissemination.
This CD109 knockout product is suitable for a broad spectrum of experimental applications, including Western blotting to quantify SMAD2/3 phosphorylation levels, RT-qPCR to profile EMT marker transcript changes, and transwell or scratch wound assays to evaluate cell migration and invasion. Additionally, it can be employed in TGF-?? response luciferase reporters and immunofluorescence microscopy to track SMAD subcellular localization. These tools are invaluable for research on TGF-?? signaling in lung cancer, tumor microenvironment interactions, therapeutic targeting of CD109, and mechanisms underlying EMT and metastasis. For further details, please contact Ascent Research.
